|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
PPARα agonists (fibrates) and PPARγ agonists (thiazolidinediones) are used for the treatment of hypertriglyceridemia and type 2 diabetes, respectively.
|
31825687 |
2020 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Pemafibrate is the first clinically-available selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that has been shown to effectively improve hypertriglyceridemia and low high-density lipoprotein cholesterol (HDL-C) levels.
|
31766193 |
2019 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Rosa rugosa flavonoids exhibited PPARα agonist-like effects on genetic severe hypertriglyceridemia of mice.
|
31100436 |
2019 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Fenofibrate, a peroxisome proliferator-activated receptor-α (PPARα) agonist, is used to treat patients with hypercholesterolemia and hypertriglyceridemia in order to reduce the risk of development of the atherosclerotic cardiovascular disease.
|
31237119 |
2019 |
|
Hypertriglyceridemia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Fenofibrate, a third-generation fibric acid derivative, is an activator of PPARα indicated for the treatment of mixed dyslipidemia and hypertriglyceridemia in adults.
|
30970278 |
2019 |
|
Hypertriglyceridemia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The results obtained in the codominant and overdominant models for the <i>PPAR-y</i> polymorphism showed a tendency to statistical significance (the C/G genotype inclined to hypertriglyceridemia), and were statistically significant in the codominant, dominant, and recessive models (the C/C genotype predisposed to increased blood pressure).
|
29315078 |
2018 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Gemfibrozil, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely used for hypertriglyceridaemia and mixed hyperlipidaemia.
|
28374976 |
2017 |
|
Hypertriglyceridemia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In relation to its effects on the hyperglycemia and hypertriglyceridemia, few is known about the mechanisms in which this compound may be acting, therefore, the aim of the present study was to determine if CGA acts as an insulin secretagogue increasing intracellular calcium concentrations ([Ca<sup>2+</sup>]<sub>i</sub>) in RINm5F cells; or as an insulin sensitizer and lipid-lowering agent stimulating the expression of PPARγ and PPARα, respectively, in 3T3-L1 adipocytes.
|
28759754 |
2017 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Treatment of hypertriglyceridaemia is based on fibrates, which activate the peroxisome proliferator-activated receptor alpha (PPARα).
|
28251701 |
2017 |
|
Hypertriglyceridemia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study.
|
28361462 |
2017 |
|
Hypertriglyceridemia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Periostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.
|
25003192 |
2014 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, has been used for decades to treat hypertriglyceridaemia and mixed dyslipidaemia.
|
24529079 |
2014 |
|
Hypertriglyceridemia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
This study examined the main effects of both single-locus and multilocus interactions among genetic variants in Chinese Han individuals to test the hypothesis that PPAR-α/δ/γ polymorphisms may contribute to the etiology of hypertriglyceridemia independently and/or through such complex interactions.
|
23262340 |
2013 |
|
Hypertriglyceridemia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
|
19362162 |
2009 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
One potential advantage in studying PPARalpha agonists is that they have been very well tolerated when used in humans to treat conditions such as elevated triglycerides.
|
16484546 |
2006 |
|
Hypertriglyceridemia
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.
|
15309680 |
2004 |
|
Hypertriglyceridemia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We assessed, in the Quebec City population, the allele frequency and haplotype distributions of mutations in genes related to HTG, such as the apolipoprotein E (APOE) (C112R and C158R), the apolipoprotein CIII (APOC3) (C-482T and C3238G) and the peroxisome proliferator-activated receptor alpha (PPARalpha) (L162V) genes.
|
15549499 |
2004 |